Latest news
RM-718 shows 11.6% BMI reduction in acquired hypothalamic obesity trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Wed, 05 Aug 2026 07:37:44 GMTTonix Gets FDA Alignment on TNX-4800 Phase 2 Lyme Disease Study Design - The Clinical Trial VanguardThe Clinical Trial Vanguard · Wed, 05 Aug 2026 06:33:35 GMTPsilocybin Has Crossed the Evidence Threshold. Clinical Guidelines Have Not. - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 12:08:27 GMTTonix Pharmaceuticals Announces FDA Alignment on 3,300‑Participant Adaptive Phase 2 Lyme Study; TNX-4800 Dosing, 2027 Site Delivery - TradingViewTradingView · Mon, 03 Aug 2026 11:23:01 GMTTonix Plans Two-Dose Antibody Study; Protection Expected in 2 Days - Stock TitanStock Titan · Mon, 03 Aug 2026 11:00:00 GMT